CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-04 | Miller Edward General Counsel | Sale | −424 | $0.64 | $271 | 235,534 |
| 2024-01-04 | Brainard Diana Chief Executive Officer | Sale | −1,664 | $0.64 | $1K | 873,242 |
| 2024-01-04 | Hagen Brett R Chief Accounting Officer | Sale | −310 | $0.64 | $198 | 97,190 |
| 2023-12-27 | Hagen Brett R Chief Accounting Officer | Sale | −28,335 | $0.74 | $21K | 97,500 |
| 2023-11-20 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −4,382 | $1.69 | $7K | 874,906 |
| 2023-11-17 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −403 | $1.63 | $657 | 125,835 |
| 2023-11-17 | Sinha Vikas See Remarks | Sale 10b5-1 | −2,490 | $1.63 | $4K | 1,167,749 |
| 2023-11-17 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −2,689 | $1.63 | $4K | 879,288 |
| 2023-10-20 | Sinha Vikas See Remarks | Sale 10b5-1 | −1,475 | $1.54 | $2K | 1,170,239 |
| 2023-10-20 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −357 | $1.54 | $550 | 126,238 |
| 2023-10-19 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −8,581 | $1.58 | $14K | 881,977 |
| 2023-10-19 | Sinha Vikas See Remarks | Sale 10b5-1 | −1,232 | $1.58 | $2K | 1,171,714 |
| 2023-10-19 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −358 | $1.58 | $566 | 126,595 |
| 2023-10-03 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −1,325 | $1.98 | $3K | 890,558 |
| 2023-10-03 | Sinha Vikas See Remarks | Sale 10b5-1 | −755 | $1.98 | $1K | 1,172,946 |
| 2023-10-03 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −222 | $1.98 | $439 | 126,953 |
| 2023-08-18 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −4,055 | $2.79 | $11K | 891,883 |
| 2023-08-17 | Sinha Vikas See Remarks | Sale 10b5-1 | −10,516 | $2.50 | $26K | 1,173,701 |
| 2023-08-17 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −11,361 | $2.50 | $28K | 895,938 |
| 2023-08-17 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −1,653 | $2.50 | $4K | 127,175 |
Page 8 of 13 · 259 trades